样式: 排序: IF: - GO 导出 标记为已读
-
N-Acetylcysteine To Reduce Mortality For Patients Requiring Cardiac Catheterization or Cardiac Surgery: A Systematic Review And Meta-Analysis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-03-06 Clement Gakuba, Alexandru-Daniel Dumitrascu, Pierre-Emmanuel Marson, Damien Legallois, Jean-Luc Hanouz, Denis Vivien, Sara Martinez De Lizarrondo, Maxime Gauberti, Damiano Cerasuolo
Multimers of von Willebrand factor (VWF) play a critical role in various processes inducing morbidity and mortality in cardiovascular risk patients. With the ability to reduce VWF multimers, N-acetylcysteine (NAC) could reduce mortality in patients undergoing coronary catheterization or cardiac surgery. However, its impact in perioperative period has never been studied so far in regard of its potential
-
Atherosclerotic Plaque Erosion: Mechanisms, Clinical Implications, and potential therapeutic Strategies - a review. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-29 Sharon Bruoha, Mattia Galli, Pierre Sabouret, Chaim Yosefy, Louay Taha, Felice Gragnano, Michael P Savage, Mony Shuvy, Giuseppe Biondi-Zoccai, Michael Glikson, Elad Asher
Atherosclerosis is an insidious and progressive inflammatory disease characterized by the formation of lipid-laden plaques within the intima of arterial walls with potentially devastating consequences. While rupture of vulnerable plaques has been extensively studied, a distinct mechanism known as plaque erosion has gained recognition and attention in recent years. Plaque erosion, characterized by the
-
Transcriptome Analysis Reveals Enhancement of Cardiogenesis-Related Signaling Pathways by S-nitroso-N-pivaloyl-D-penicillamine (SNPiP): Implications for Improved Diastolic Function and Cardiac Performance. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-29 Yasuhiro Takenaka, Masataka Hirasaki, Hidemasa Bono, Shigeo Nakamura, Yoshihiko Kakinuma
We previously reported a novel compound called S-nitroso-N-pivaloyl-D-penicillamine (SNPiP), which was screened from a group of nitric oxide (NO) donor compounds with a basic chemical structure of S-nitroso-N-acetylpenicillamine (SNAP), to activate the non-neuronal acetylcholine (NNA) system. SNPiP-treated mice exhibited improved cardiac output and enhanced diastolic function, without an increase in
-
Novel therapeutic insights into the treatment of pericarditis: Targeting the innate immune system. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-29 Alessandra Vecchié, Aldo Bonaventura, Michele Golino, Georgia Thomas, Antonio Abbate
Acute pericarditis is characterized by pericardial inflammation which can be treated with anti-inflammatory drugs. A considerable percentage of patients develops recurrent pericarditis with several relapses. In developed countries, the idiopathic form is the most frequent and has a high risk of recurrences. Two pathophysiological mechanisms have been described for idiopathic recurrent pericarditis
-
Association of IL-17 Inhibitors with Hypertension in Patients with Autoimmune Diseases: A Systematic Review and Meta-analysis on Randomized Controlled Trials. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-27 Kexin Jiang, Yuheng Jia, Li Chen, Fangyang Huang, Mao Chen
The influence of IL-17 inhibition on blood pressure in autoimmune disease patients remains inconclusive. Our objective is to examine the risk of hypertension in patients with autoimmune diseases undergoing IL-17 inhibition therapies via meta-analysis of randomized, placebo-controlled trials (RCTs). We obtained integrated data from PubMed, Embase, and ClinicalTrials.gov. Incident hypertension rates
-
Protective Effect of CD137 Deficiency against Post-infarction Cardiac Fibrosis and Adverse Cardiac Remodeling via ERK1/2 Signaling Pathways. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-12 Guangyao Zang, Yiliu Chen, Ge Guo, Aijun Wan, Bo Li, Zhongqun Wang
Myocardial fibrosis, a common complication of myocardial infarction (MI), is characterized by excessive collagen deposition and can result in impaired cardiac function. The specific role of CD137 in the development of post-MI myocardial fibrosis remains unclear. Thus, this study aimed to elucidate the effects of CD137 signaling using CD137 knockout mice and in vitro experiments. CD137 expression levels
-
Current treatment and immunomodulation strategies in Acute Myocarditis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-09 Emma Ferone, Amitai Segev, Erika Tempo, Piero Gentile, Ahmed Elsanhoury, Chiara Baggio, Jessica Artico, Prashan Bhatti, Paul Scott, Emanuele Bobbio, Marco Merlo, Pietro Ameri, Gianfranco Sinagra, Carsten Tschöpe, Daniel Bromage, Antonio Cannata
Myocarditis is an inflammatory disease of the myocardium characterized by a great heterogeneity of presentation and evolution. Treatment of myocarditis is often supportive and the evidence for immunosuppression is scarce and debated. Conventional treatment is based on clinical presentation, ranging from conservative to advanced mechanical assist devices. In this setting, immunosuppression and immunomodulation
-
Antithrombotic Stewardship: Evaluation of Platelet Reactivity-Guided Cangrelor Dosing Using the VerifyNow® Assay. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-08 Alexander Connery, Tania Ahuja, Alyson Katz, Serena Arnouk, Eric Zhu, John Papadopoulos, Sunil Rao, Cristian Merchan
Cangrelor may be used as a bridge when temporary interruption of dual antiplatelet therapy (DAPT) is necessary. However, the optimal dose and monitoring of cangrelor in patients remains unknown, especially in the setting of mechanical circulatory support (MCS). We conducted an observational, single-center, retrospective cohort study of patients that had PCI within 3 months and received cangrelor while
-
Exploring the Promise and Challenges of Artificial Intelligence in Biomedical Research and Clinical Practice. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-05 Raffaele Altara, Cameron J Basson, Giuseppe Biondi-Zoccai, George W Booz
Artificial intelligence (AI) is poised to revolutionize how science, and biomedical research in particular, are done. With AI, problem solving and complex tasks using massive data sets can be performed at a much higher rate and dimensionality level compared to humans. With the ability to handle huge data sets and self-learn, AI is already being exploited in drug design, drug repurposing, toxicology
-
Short-Chain Acyl-CoA Dehydrogenase as a Therapeutic Target for Cardiac Fibrosis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-02-02 Zhaohui Shu, Jingyun Feng, Lanting Liu, Yingqin Liao, Yuhong Cao, Zhenhua Zeng, Qiuju Huang, Zhonghong Li, Guifang Jin, Zhicheng Yang, Jieyu Xing, Sigui Zhou
Cardiac fibrosis is considered as unbalanced extracellular matrix (ECM) production and degradation, contributing to heart failure. Short-chain acyl-CoA dehydrogenase (SCAD) negatively regulates pathological cardiac hypertrophy. The purpose of this study was to investigate the possible role of SCAD in cardiac fibrosis. In-vivo experiments were performed on spontaneously hypertensive rats (SHR) and SCAD
-
Effect of benidipine alone and in combination with bosentan and sildenafil in amelioration of pulmonary arterial hypertension in experimental model in rats. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-17 Kalpana Kumari, Vishal Kumar Vishwakarma, Kuldeep Kumar, Asit Ranjan Mridha, Sudhir Kumar Arava, Sameer Dhingra, Nirmal Singh, Harlokesh Narayan Yadav
Pulmonary arterial hypertension (PAH) is a persistent condition affecting the pulmonary arteries' endothelium. Benidipine, a calcium channel blocker, possesses vasodilatory, anti-inflammatory activity, reduces oxidative stress, and inhibits the activity of TGF-β receptor 1 and α-SMA. The present study was designed to investigate the effect of benidipine alone and in combination with bosentan and sildenafil
-
Impact of preloading strategy with ticagrelor on periprocedural myocardial injury in patients with non-ST elevation myocardial infarction undergoing early invasive strategy. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-15 Orhan Furkan Karaca, Murat Cimci, Damla Raimoglou, Eser Durmaz, Hakan Yalman, Alpin Mert Tekin, Gunduz Incesu, Ferit Ulas Ozkan, Betul Yavuz, Bilgehan Karadag
Pretreatment with an oral P2Y12 receptor blocker (before coronary angiography) vs. treatment in the catheterization laboratory has been a matter of debate in patients presenting with non-ST segment elevation myocardial infarction (NSTEMI). The primary aim of this study was to assess the impact of an immediate preloading strategy with ticagrelor on periprocedural myocardial injury in patients with NSTEMI
-
NaHS reverts chronic stress-induced cardiovascular alterations by reducing oxidative stress. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-11 Jesus H Beltran-Ornelas, Diana L Silva-Velasco, Jorge Tapia-Martínez, Araceli Sánchez-López, Edgar Cano-Europa, Saúl Huerta de la Cruz, David Centurión
Chronic stress induces a group of unrecognized cardiovascular impairments, including elevated hemodynamic variables and vascular dysfunction. Moreover, hydrogen sulfide (H2S), a gasotransmitter that regulates the cardiovascular system, decreases under chronic stress. Thus, this study assessed the impact of NaHS (H2S donor) on chronic restraint stress (CRS)-induced cardiovascular changes. For that purpose
-
The efficacy of traditional Chinese herbal medicine across multiple cardiovascular diseases: an umbrella review of systematic reviews of randomized controlled trials. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-09 Xi Li, Tao Yu, Qin Jiang, Jin Tan, Ke Liu
Traditional Chinese herbal medicine (CHM) has been extensively used in cardiovascular disease in modern clinical practice, alone or in combination with conventional treatment. However, its efficacy has not been assessed extensively. From inception until August 2023, we systematically searched five public literature databases to conduct the umbrella review. The inclusion criterion is systematic reviews
-
Identification of M2 Macrophage-Related Key Genes in Advanced Atherosclerotic Plaques by Network Based Analysis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-09 Yao Yuan, Peng Wang, Haigang Zhang, Ya Liu
Atherosclerotic plaque accounts for major adverse cardiovascular events due to its vulnerability. The M1 and M2 macrophages are implicated in progression and regression of plaque, respectively. However, the therapeutic targets related M2 macrophages still remain largely elusive. In this study, CIBERSORT and WGCNA algorithms were employed to establish a weighted gene co-expression network for identifying
-
Tumor Necrosis Factor-α-Induced Protein-8-like 2 Transfected Adipose-Derived Stem Cells Regulated the Dysfunction of Monocrotaline Pyrrole-Induced Pulmonary Arterial Smooth Muscle Cells and Pulmonary Arterial Endothelial Cells. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-01 Jing Li, Xin He, Feng Liu, Xinglong Zheng, Jing Jiang
Pulmonary arterial hypertension (PAH) is characterized by pulmonary arterial endothelial cell (PAEC) dysfunction and pulmonary arterial smooth muscle cell (PASMC) activation. For decades, the therapies for PAH based on stem cells have been shown to be effective. Meanwhile, tumor necrosis factor-α-induced protein-8-like 2 (TIPE2) promote the viability of human amniotic mesenchymal stem cells. Therefore
-
Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-01 Yun Huang, Hua Zhou, Chongbo Fang, Lili Ma, Yuyu Zhang, Weibo Rong, Xiaoli Liu, Honghua Ye
This study aimed to compare the cost-effectiveness of the new quadruple therapy regimen of adding sodium-glucose-linked transporter 2 (SGLT2) inhibitors, with standard treatment for patients with heart failure (HF) in China. From the payer's perspective, the dates of cardiovascular event recurrences were extracted from a meta-analysis including 6 trials, combined with the treatment cost for patients
-
Cardioprotective Action of a Novel Synthetic 19,20-EDP Analog Is Sirt Dependent. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-01 Joshua W Kranrod, Ahmed M Darwesh, Wesam Bassiouni, Andy Huang, Liye Fang, Jacob V Korodimas, Adeniyi Michael Adebesin, Sailu Munnuri, John R Falck, John M Seubert
Mounting evidence suggests that cytochrome P450 epoxygenase-derived metabolites of docosahexaenoic acid, called epoxydocosapentaenoic acids (EDPs), limit mitochondrial damage after cardiac injury. In particular, the 19,20-EDP regioisomer has demonstrated potent cardioprotective action. Thus, we investigated our novel synthetic 19,20-EDP analog SA-22 for protection against cardiac ischemia-reperfusion
-
Central Sleep Apnea in Patients With Coronary Heart Disease Taking P2Y12 Inhibitors. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2024-01-01 William S Tzeng, Christian F Klein, Robert H Roth, Yeilim Cho, Rohit Munagala, Heather Bonner, Sula Mazimba, Rami Khayat, William Healy, Jennifer M Lobo, Vishesh K Kapur, Younghoon Kwon
Central sleep apnea (CSA) is common in patients with heart failure. Recent studies link ticagrelor use with CSA. We aimed to evaluate CSA prevalence in patients with coronary heart disease (CHD) and whether ticagrelor use is associated with CSA. We reviewed consecutive patients with CHD who underwent a polysomnography (PSG) test over a 5-year period from 3 sleep centers. We sampled patients who were
-
Contractile effects of amphetamine, pseudoephedrine, nor-pseudoephedrine (cathine) and cathinone on atrial preparations of mice and humans. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-29 Joachim Neumann, Wilhelm Hußler, Britt Hofmann, Ulrich Gergs
Amphetamine derivatives are used worldwide legally or illegally and intoxications may be accompanied by cardiac arrhythmias. Here, we tested contractile effects of cumulative applied (±)-amphetamine, pseudoephedrine, nor-pseudoephedrine (cathine) and cathinone in electrically stimulated (1 Hz) human right atrial preparations (HAP) and mouse left atrial preparations (LA) as well as in spontaneously
-
Efficacy and safety of colchicine for the prevention of postoperative atrial fibrillation among patients undergoing major cardiothoracic surgery: a meta-analysis and meta-regression of randomized controlled trials. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-28 Frederick Berro Rivera, Sung Whoy Cha, John Paul Aparece, Sathika Jariyatamkitti, Mamas Mamas
The role of colchicine for the prevention of postoperative atrial fibrillation (POAF) following cardiothoracic surgery is not well-established. We aimed to evaluate its potential in preventing POAF using data from randomized controlled trials (RCTs). A literature search was performed to identify studies reporting POAF as an outcome after cardiac or thoracic surgery in adult patients randomized to either
-
The Role of Rosmarinic Acid in the Protection against Inflammatory Factors in Rats Model with Monocrotaline-Induced Pulmonary Hypertension: Investigating the Signaling Pathway of NFκB, OPG, Runx2, and P-selectin in Heart. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-26 Narges Atefipour, Mahin Dianat, Mohammad Badavi, Maryam Radan, Seyyed Ali Mard
Shortness of breath and syncope are common symptoms of right ventricular failure caused by pulmonary arterial hypertension (PAH), which is the result of blockage and increased pressure in the pulmonary arteries. There is a significant amount of evidence supporting the idea that inflammation and vascular calcification are important factors in PAH pathogenesis. Therefore, we aimed to investigate the
-
The Impact of Midodrine On Guideline-Directed Medical Therapy in Patients Admitted with Systolic Heart Failure. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-21 Christopher B Scoma, Dae Hyun Lee, David Money, Gerry Eichelberger, Ahsan Usmani, Adam J Cohen, Joel Fernandez
Midodrine is occasionally used off-label to treat hypotension associated with advanced heart failure. Its association with changes in prescription of guideline-directed medical therapy (GDMT) is unknown.
-
Effect of three-day atorvastatin administration on coagulation factors in patients with prior venous thromboembolism and healthy subjects. A preliminary study. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-20 Konrad Stępień, Marek Żółciński, Michał Ząbczyk, Jarosław Zalewski, Anetta Undas
Statins exert antithrombotic effects, which might contribute to reduced risk of venous thromboembolism (VTE). Rosuvastatin 20 mg/d administered for 4 weeks has been reported to decrease coagulation factors (F) VII, FVIII, and FXI in VTE patients. Moreover, in accordance with recent registry data in non-VTE subjects statins usage was associated with lower FXI. We investigated whether three doses of
-
Levosimendan Relaxes Thoracic Aortic Smooth Muscle in Mice by Inhibiting PKC and Activating Inwardly Rectifying Potassium Channels. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-15 Cai-Hong Yang, Hui-Qin Qiu, Chan Wang, Ya-Ting Tang, Cheng-Rui Zhang, Yan-Ying Fan, Xiang-Ying Jiao
Studies have examined the therapeutic effect of levosimendan on cardiovascular diseases such as heart failure, perioperative cardiac surgery, and septic shock, but the specific mechanism in mice remains largely unknown. This study aimed to investigate the relaxation mechanism of levosimendan in the thoracic aorta smooth muscle of mice. Levosimendan-induced relaxation of isolated thoracic aortic rings
-
LncRNA MALAT1-targeting antisense oligonucleotide ameliorates the AngII-induced vascular smooth muscle cell proliferation and migration via Nrf2/GPX4 antioxidant pathway. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-12 Zili Liao, Zhonghan Ni, Jun Cao, Jin Liao, Hengqing Zhu, Xiutong Zhong, Gang Cao, Ling Huang, Xiaoyue Li, Guojun Jiang, Fang Pei
The high level of oxidative stress induced by angiotensin II (AngII) is the main pathophysiological process that promotes the proliferation and migration of vascular smooth muscle cells (VSMCs) and induces vascular remodeling. LncRNA Metastasis-related lung adenocarcinoma transcript 1 (MALAT1) has been determined to play an important role in the modulation of oxidative stress and the development of
-
Heparin Dosing During Percutaneous Coronary Intervention and Obesity. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-12-12 Rolf P Kreutz, Isaac G Leon, Eric R Bain, Bistees George, Sujoy Phookan, Anjali Prakash, Anjan K Sinha, Jeffrey A Breall, Joseph R Zenisek, Kyle A Frick, Ziad A Jaradat, Ibrahim S Abu Romeh, Brian O'Leary, Ankur Kalra, Ashish Kumar, Michael S Lee, Elisabeth von der Lohe
Unfractionated heparin is the most common anticoagulant used during percutaneous coronary intervention (PCI). Practice guidelines recommend an initial weight-based heparin bolus dose between 70 to 100 U/kg to achieve target activated clotting time (ACT) of 250-300 seconds. The impact of severe obesity on weight-based heparin dosing is not well studied. We performed a retrospective analysis of 424 patients
-
Naturally Occurring Atherosclerosis Progression and In-Stent Restenosis: Exploring Histomorphological Associations Using Optical Coherence Tomography. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-27 Wei Zhang, Wei Zhang, Ning Gu, Zhimei Qiu, Li Pan, Yongchao Zhao, Bei Shi
The mechanism of in-stent restenosis (ISR) remains elusive, and in-stent neoatherosclerosis (ISNA) may hold siginificant pathophysiological implications. Nevertheless, the correlation between ISNA and the progression of untreated coronary segments affected by native atherosclerosis remains incompletely investigated. This study enrolled 225 patients diagnosed with coronary heart disease and multivessel
-
Pde5 Inhibition Reduced Blood Pressure and Alleviated Target Organ Damage in Chronic Intermittent Hypoxia. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-23 Siyi Li, Qingjie Xin, Yan Yan, Xiao Wang, Hui Ai, Bin Que, Wei Gong, Shaoping Nie
The role of phosphodiesterase 5 (Pde5) in obstructive sleep apnea (OSA) induced damage remains unclear. Our study aimed to investigate the role of Pde5 in chronic intermittent hypoxia (CIH) model. C57BL/6J wild-type (WT) mice (n=48) and Pde5 knockout (Pde5-/-) mice (n=24) were randomly assigned to CIH group and room air (RA) group. After 6 weeks, some WT mice (n=24) in CIH group were given sildenafil
-
Anti-platelet agents inhibit platelet adhesion and aggregation on glass surface under physiological flow conditions: Toward a microfluidic platelet functional assay without additional adhesion protein modification. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-23 Zhanshu Liu, Xiaojing Huang, Xuemei Gao, Tiancong Zhang, Cui He, Ling Ding, Yuan Li
As the pathogenesis of arterial thrombosis often includes platelet adhesion and aggregation, antiplatelet agents are commonly used to prevent thromboembolic events. Here, a new microfluidic method without additional adhesion protein modification was developed to quantify the inhibitory effect of antiplatelet drugs on the adhesion and aggregation behavior of platelets on glass surfaces under physiological
-
A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-22 Qian Sun, Wenyan Cui, Xinhui Zhang, Yunfei Tian, Guangliang Huang, Wenjuan He, Yonghong Zhao, Xiaojuan Zhao, Dan Li, Xiuju Liu
To systematically evaluate the efficacy and safety of renin-angiotensin inhibitors (RASIs) and angiotensin receptor neprilysin inhibitors (ARNI) in preventing the recurrence of atrial fibrillation after atrial fibrillation ablation, we have written this meta-analysis. We systematically searched randomized controlled trials or cohort studies on renin-angiotensin inhibitors and angiotensin receptor neprilysin
-
Non-dual antiplatelet therapy versus dual antiplatelet therapy prior to transcatheter aortic valve replacement: A systematic review and meta-analysis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-22 Mengdi Zhang, Wenxing Peng, Shiqi Yin, Yiru Zhao, Yang Lin
Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR. However, few studies have investigated the prognostic effect of preoperative antiplatelet therapy in patients undergoing TAVR. This study aimed
-
Dapagliflozin Suppresses Isoprenaline-Induced Cardiac Hypertrophy via Inhibition of Mitochondrial Fission. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-22 Zhuo-Jing Yang, Chun-Ling Guo, Yu-Xin Gong, Long Li, Li-Li Wang, Hui-Min Liu, Ji-Min Cao, Zhao-Yang Lu
Dapagliflozin (DAPA) is a novel oral hypoglycemic agent, and there is increasing evidence that DAPA has a protective effect against cardiovascular disease. The study aimed to investigate how DAPA inhibits cardiac hypertrophy and explore its potential mechanisms. By continuously infusing isoprenaline (ISO) for two weeks using a subcutaneous osmotic pump, a cardiac hypertrophic model was established
-
Repeated levosimendan infusions in the management of advanced heart failure: review of the evidence and meta-analysis of the effect on mortality. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-22 Simona Silvetti, Piero Pollesello, Alessandro Belletti
In the latest years several studies described the impact of repetitive/intermittent i.v levosimendan treatment in the management of advanced heart failure. For this updated review we systematically searched the literature for clinical trials, registries, and real-world data, and identified 31 studies that we commented in a narrative review: 3814 patients were described, of whom 1744 were treated repetitively
-
Acetylated Histone Modifications: Intersection of Diabetes and Atherosclerosis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-17 Runyang Liu, Lihua Li, Zhongqun Wang, Jie Zhu, Yu Ji
Worldwide, type 2 diabetes is predominant form of diabetes, and it is mainly affected by the environment. Furthermore, the offspring of patients with type 2 diabetes and metabolic disorder syndrome may have a higher risk of diabetes and cardiovascular disease, which indicates that the environmental impact on diabetes prevalence can be transmitted across generations. In the process of diabetes onset
-
Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in Heart Failure (LILAC-HF). J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-17 Megan Lai, Jade C Lam, John J Radosevich, Asad E Patanwala, Rajakrishnan Vijayakrishnan
Management of heart failure (HF) requires the use of loop diuretics to relieve congestion and improve symptoms. When loop diuretics alone fail to induce adequate diuresis, albumin has been proposed to enhance loop diuretic delivery and promote redistribution of fluid for excretion by the kidneys. Despite the theoretical benefits of albumin, studies suggesting its benefit in HF are scarce and the co-administration
-
ALKBH5 regulates N(6)-methyladenosine (m6A) methylation of MG53 to attenuate myocardial infarction by inhibiting apoptosis and oxidative stress. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-17 Dong Li, Lianggang Li, Shiyong Dong, Yaqun Yu, Lin Zhang, Shengli Jiang
N(6)-methyladenosine (m6A) methylation modification is involved in the progression of myocardial infarction (MI). In this study, we investigated the effects of demethylase ALKBH5 on cell apoptosis and oxidative stress in MI. The ischemia/reperfusion (I/R) injury mouse model and hypoxia/reoxygenation (H/R) cell model were established. The levels of ALKBH5 and MG53 were measured by quantitative real-time
-
The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-15 Sharath Kommu
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in patients with heart failure (HF). However, studies examining their benefits exclusively in nondiabetic patients on various HF outcomes are limited. By conducting a MEDLINE and ClinicalTrials.gov search for randomized controlled trials, we identified four studies on SGLT2i with data on HF outcomes in nondiabetic patients
-
Different anti-inflammatory drugs on high-sensitivity C-reactive protein in patients after percutaneous coronary intervention: A pilot randomized clinical trial. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-07 Miao Yu, Zheng-Feng Zhu, Fen Yang, Yuan-Fan Yuan, Shu-De Liao, Mei-Lin Liu, Xiang Cheng
Colchicine reduces atherothrombotic cardiovascular events in coronary artery disease (CAD) due to its anti-inflammatory effect. However, the effects of the other anti-inflammatory drugs in CAD remain unclear. This study included 132 patients aged 18-80 years who completed the planned percutaneous coronary interventions (PCI) and were treated with aggressive secondary prevention strategies for four
-
Duration Of Dual Antiplatelet Treatment After Percutaneous Coronary Intervention In Patients With Diabetes: A Systematic Review And Meta-Analysis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-11-07 Anastasios Apostolos, Christofer Travlos, Georgios Tsioulos, Dimitrios-David Chlorogiannis, Antonios Karanasos, Michael Papafaklis, Dimitrios Alexopoulos, Konstantinos Toutouzas, Periklis Davlouros, Grigorios Tsigkas
Aim of our systematic review and meta-analysis is to compare shortened (≤3 months) dual antiplatelet therapy (DAPT) with longer DAPT in diabetic patients undergoing percutaneous coronary interventions (PCI).We systematically screened three major databases (Medline, Cochrane Central Register of Controlled Trials and Scopus) searching for randomized-controlled trials or sub-analyses of them, which compared
-
An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-27 Alfredo Caturano, Vincenzo Brunelli, Serenella Spiezia, Raffaele Galiero, Marcellino Monda, Vincenzo Russo, Ferdinando Carlo Sasso
Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), stands as the third leading cause of vascular-related mortality on a global scale. Anticoagulation prophylaxis undeniably ensures a significant reduction in the risk of DVT, while simultaneously exposing individuals to an elevated likelihood of experiencing both major and minor bleeding events. Betrixaban
-
Ferroptosis Involved in Cardiovascular Diseases: Mechanism Exploration of Ferroptosis' Role in Common Pathological Changes. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-27 Dongjie Gao, Leilei Hu, Hao Lv, Lu Lian, Mingyang Wang, Xinbiao Fan, Yingyu Xie, Junping Zhang
Regulated cell death is a controlled form of cell death that protects cells by adaptive responses in pathophysiological states. Ferroptosis has been identified as a novel method of controlling cell death in recent years. Several cardiovascular diseases (CVDs) are shown to be profoundly influenced by ferroptosis, and ferroptosis is directly linked to the majority of cardiovascular pathological alterations
-
The STING-IRF3 signaling pathway, mediated by endoplasmic reticulum stress, contributes to impaired myocardial autophagic flux following ischemia/reperfusion. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-18 Yuanbin Li, Hui Lin, Hao Tang, Ke Zhu, Zhangfu Zhou, Zhaohui Zeng, Bin Pan, Zhuang Chen
This study aimed to determine whether endoplasmic reticulum (ER) stress is involved in impaired autophagy after myocardial ischemia/reperfusion I/R (M-I/R) and elucidate the underlying mechanisms. The expression levels of STING and IRF3 phosphorylation increased in M-I/R heart tissues and hypoxia/reoxygenation (H/R)-treated H9c2 cells. The ER stress inhibitor 4-phenylbutyric acid (4-PBA)significantly
-
Preclinical Study on a Novel Fluoroderivative of Dabigatran Etexilate in Animal Models. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-13 Yujie Ren, Chunlei Li, Yujia Zhang
Here, the fluorinated derivative, R1, was synthesized from the fluorinated dabigatran derivative (R0). The in vivo pharmacokinetic characteristics of orally administered R1, R0 injection, and dabigatran etexilate in rats were compared. Safety evaluation results showed no significant changes in the QRS wave or PR and QT intervals in rat lead II electrocardiograms. The possible toxicity of R1 was studied
-
Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Heart Failure in China: a new pillar in our pockets, but at what price? J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-10 Massimiliano Camilli, Federico Ballacci, Federica Giordano, Giorgio Minotti
Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important pharmacological innovations in the field of Cardiology of the last decades, having shown significant outcome improvement in all the heart failure (HF) spectrum. However, cost-effectiveness considerations should be made. This editorial discusses results of a cost-effectiveness study coming from China and focusing on
-
Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-10 Ehsan Jafree, Marco Guiseppe Del Buono, Justin M Canada, Salvatore Carbone, Jordana Kron, Ross Arena, Benjamin Van Tassell, Antonio Abbate, Cory R Trankle
Heart failure (HF) is a complex syndrome that remains a leading cause of morbidity and mortality worldwide. Abundant evidence suggests inflammation plays a key role in the development and perpetuation of HF, but there are currently no anti-inflammatory treatments approved for use in HF. Interleukin-1 (IL-1), the prototypical pro-inflammatory cytokine, has been implicated in adverse cardiac remodeling
-
The therapeutic potential of targeting ferroptosis in the treatment of mitochondrial cardiomyopathies and heart failure. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-10 Aubrey C Cantrell, Heng Zeng, Jian-Xiong Chen
Ferroptosis is a form of iron-regulated cell death implicated in a wide array of diseases, including heart failure, hypertension, and numerous cardiomyopathies. Additionally, mitochondrial dysfunction has been associated with several of these same disease states. However, the role of the mitochondrion in ferroptotic cell death remains debated. As a major regulator of cellular iron levels, the mitochondria
-
Aldehyde dehydrogenase 2 preserves mitochondrial function in the ischemic heart: a redox-dependent mechanism for AMPK activation by thioredoxin-1. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-10 Yi Zhu, Ya-Jun He, Yuan Yu, Dan Xu, Shi-Ying Yuan, Hong Yan
Aldehyde dehydrogenase 2 (ALDH2) protects the ischemic heart by activating AMP-activated protein kinase (AMPK) signaling. However, the molecular mechanisms linking ALDH2 and AMPK signaling are not fully understood. This study aimed to explore the potential mechanisms linking ALDH2 and AMPK in myocardial ischemic injury. An ischemic model was established by ligating the left anterior descending coronary
-
Prior use of Angiotensin converting enzyme inhibitors (ACEi) or Angiotensin II receptor blockers (ARBs) and clinical outcomes of sepsis and septic shock: A systematic review and meta-analysis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-09 Dhan Bahadur Shrestha, Yub Raj Sedhai, Prakash Raj Oli, Ekaterina Proskuriakova, Alla Adelkhanova, Jurgen Shtembari, Tahir Muhammad Abdullah Khan, Karan Singh, Muhammad Altaf Ahmed, Irfan Waheed, Nisarfathima Kazimuddin, Rodney Steff, Roshan Acharya, Nimesh K Patel
Sepsis and septic shock are life-threatening conditions which are associated with high mortality and considerable healthcare costs. The association between prior angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) use and outcomes following sepsis is elusive. The aim of this study is to evaluate the role of the prior use of ACEi and ARBs and outcomes post sepsis
-
Evaluation and management of pericarditis in rheumatic diseases. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-10-09 Yumeko Kawano, Maria A Pabón, Candace H Feldman, Sarah Cuddy, Leonard S Lilly, Michael S Garshick, Brittany Weber
This review summarizes the evaluation for underlying rheumatic conditions in patients presenting with acute pericarditis, treatment considerations for specific rheumatic conditions, and the role of imaging in diagnosis and monitoring. Pericarditis may be one of the initial presentations of a rheumatic disease or identified in a patient with known rheumatic disease. There is also growing evidence for
-
Overexpression of human soluble epoxide hydrolase exacerbates coronary reactive hyperemia reduction in Angiotensin-II treated mouse hearts. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-29 Ahmad Hanif, Matthew L Edin, Darryl C Zeldin, Mohammed A Nayeem
Coronary reactive hyperemia (CRH) is impaired in cardiovascular diseases, and angiotensin-II (Ang-II) exacerbates it. However, it is unknown how Ang-II affects CRH in Tie2-sEH Tr (human-sEH-overexpressed) versus wild-type (WT) mice. sEH-overexpression resulted in CRH-reduction in Tie2-sEH Tr versus WT. We hypothesized that Ang-II exacerbates CRH-reduction in Tie2-sEH Tr versus WT. Coronary flow in
-
GPER acts through the cAMP/Epac/JNK/AP-1 pathway to induce transcription of alpha 2C adrenoceptor in human microvascular smooth muscle cells. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-28 Manal Fardoun, Suzanne A Nasser, Ahmed F El-Yazbi, Ali H Eid
Raynaud's phenomenon (RP), which results from exaggerated cold-induced vasoconstriction, is more prevalent in females than males. We previously showed that estrogen increases the expression of alpha 2C-adrenoceptors (α2C-AR), the sole mediator of cold-induced vasoconstriction. This effect of estrogen is reproduced by the cell-impermeable form of the hormone (E2:BSA), suggesting a role of the membrane
-
Golgi protein 73 promotes LPS-induced cardiac dysfunction via mediating myocardial apoptosis and autophagy. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-26 Yaqi Xing, Zhenqiang Gao, Yunfei Bai, Wen Wang, Chen Chen, Yuanyuan Zheng, Yan Meng
Sepsis-induced cardiac dysfunction represents a major cause of high mortality in intensive care units with limited therapeutic options. Golgi protein 73 (GP73) has been implicated in various diseases. However, the role of GP73 in LPS-induced cardiac dysfunction is unclear. Here, we established sepsis-induced cardiac dysfunction model by LPS administration in wild type (WT) and GP73 knockout (GP73-/-)
-
An Update on Betrixaban, The Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-20 Yasaman Daryabari, Fnu Amreek, Ali Akbar Moghadamnia, Pouya Tayebi
Venous thromboembolism (VTE) is a prevalent yet preventable cause of death, particularly among hospitalized patients. Studies have shown that the risk of VTE remains high for up to 6 months after discharge, highlighting the need for extended thromboprophylaxis as a viable treatment approach. Despite the availability of several anticoagulant drugs like vitamin K antagonists, heparinoids, rivaroxaban
-
Transcription factor TCF3 promotes macrophage-mediated inflammation and MMPs secretion in abdominal aortic aneurysm by regulating miR-143-5p/CCL20. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-18 Yuejin Li, Rougang Li, Yu Li, Guosan Li, Yiman Zhao, Houyu Mou, Yi Chen, Le Xiao, Kunmei Gong
Damage to the abdominal aortic wall and the local inflammatory response are key factors resulting in abdominal aortic aneurysm (AAA) formation. During this process, macrophage polarization plays a key role. However, in AAA, the regulatory mechanism of macrophages is still unclear, and further research is needed. In this study, we found that the transcription factor TCF3 was expressed at low levels
-
Recent Progress in The Development and Clinical Application of New Drugs for Transthyretin Cardiac Amyloidosis. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-06 Juan Zhou, Yanfang Li, Jing Geng, Hong Zhou, Lian Liu, Xiaochun Peng
Transthyretin cardiac amyloidosis is a rare disease that has gained significant attention in recent years due to misfolding of transthyretine fibrils produced by the liver, leading to their deposition in the myocardium. The disease has an insidious onset, nonspecific clinical manifestations, and historically lacked effective drugs, making early diagnosis and treatment challenging. The survival time
-
Post-acute myocardial infarction heart failure core genes and relevant signaling pathways. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-06 Ling Lin, Ling Zicheng, Gu Shaohua
There is increasing concern about heart failure after myocardial infarction and the current clinical treatment measures for ventricular remodeling. Herein we present the results of differential gene analysis, pathway enrichment analysis, and characteristic gene screening. Our study identifies four core genes (KLRC2, SNORD105, SNORD45B, and RNU5A-1) associated with post-AMI heart failure. The authors
-
MiR-590-3p promotes the phenotypic switching of vascular smooth muscle cells by targeting LOX. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-05 Lei Wang, Lin Zhang, Li-Kun Cui, Xiao Yue, Li Huang, Na Liu, Meng-Die Zhu, Zheng-Bin Wang
We investigated the clinical characteristics of patients with acute aortic dissection (AAD) and miR-590-3p levels in serum, tissue, and vascular smooth muscle cells (VSMCs). The effect of miR-590-3p on the VSMC phenotype was assessed, and the regulation of lysyl oxidase (LOX) by miR-590-3p was determined. C57BL/6 mice were used to investigate the incidence of AAD and effects of miR-590-3p on AAD. MiR-590-3p
-
Targeting pharmacotherapies for inflammatory and cardiorenal endpoints in kidney disease. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-05 Daniel M Huck, Leo F Buckley, Anil Chandraker, Ron Blankstein, Brittany Weber
Inflammation is an important contributor to excess cardiovascular risk and progressive renal injury in people with CKD. Dysregulation of the innate and adaptive immune system is accelerated by CKD and results in increased systemic inflammation, a heightened local vascular inflammatory response leading to accelerated atherosclerosis, and dysfunction of the cardiac and renal endothelium and microcirculation
-
Potential biomarker of acute anthracycline-induced cardiotoxicity among children with acute lymphoblastic leukemia: cardiac adriamycin-responsive protein. J. Cardiovasc. Pharmacol. (IF 3.0) Pub Date : 2023-09-01 Yiyang Li, Chuan Tian, Si Huang, Yajun Wang, Jiapeng Qiu, Fan Ning, Junhao Guo, Qikang Chen, Riling Chen, Guoda Ma
This study aimed to investigate whether serum cardiac adriamycin-responsive protein (CARP) can serve as a sensitive and specific biomarker of Anthracyclines (ANT)-induced cardiotoxicity. Fifty-five children with acute lymphoblastic leukemia (ALL) were recruited. Before and after the administration of ANT, serum levels of CARP, high-sensitivity troponin T (TNT-HS), Creatine Kinase-MB (CK-MB), and electrocardiogram